Speaker

Baum Hedlund Aristei & Goldman

Speaker Bio

Brent Wisner is an attorney and senior shareholder in the Los Angeles office of Baum Hedlund Aristei & Goldman. A Los Angeles native, Brent is driven by a deep-rooted passion for using the law to help those who have been marginalized and hurt by large, and sometimes malicious, corporations. Brent has dedicated his practice to vindicating his client’s rights and holding wrongdoers accountable. He concentrates his practice on pharmaceutical class action litigation, toxic-tort injuries, whistleblower and qui tam claims, and consumer fraud litigation. 

Brent is one of Baum Hedlund’s lead trial attorneys and manages a highly-trained team of attorneys on all aspects of the cases in his department. He takes pride in personally working up all facets of litigation-from briefing, expert discovery, through trial and, if needed, appeal. After obtaining two landmark verdicts against Monsanto, he has been showered with major awards and recognition. He is the youngest attorney to ever obtain a multi-billion-dollar verdict.

Pharmaceutical Litigation

Law360 named Mr. Wisner a “Titan of the Plaintiffs Bar” for, in part, his role as co-lead counsel in a complex trial that resulted in the first multi-million-dollar jury verdict against a brand-name drug-maker, GSK, holding it liable for injuries caused by a generic version of the drug Paxil. The case has been described as groundbreaking and likely to shape the landscape of pharmaceutical litigation for years to come. Also, because of this cutting-edge verdict, The National Law Journal recognized Brent and the firm as 2018 Elite Trial Lawyers and the first place winner in the category of Pharmaceutical Litigation.

One of the Leading Zantac Lawyers in the Country

In 2019, Brent and his colleagues filed lawsuits against the manufacturers of Zantac (ranitidine) alleging the popular heartburn medication contains a cancer-causing chemical (NDMA) at levels over 3,000 times greater than the FDA’s legal limit. The lawsuits were among the first of what will likely be many thousands. “Based on recent scientific findings, the levels of NDMA in Zantac are staggering,” says Wisner. “Considering how many people took Zantac in the U.S. since 1983, we are staring into the face of a public health crisis, and these defendants—in particular GSK and Pfizer—are to blame.”

The judge overseeing the multi-district litigation (MDL No. 2924, where all of the cases filed in federal courts are consolidated) appointed Brent to the Practices and Procedures Team to help establish the protocols and methodology for litigating tens of thousands of cases in the years to come. Brent also serves as Co-Chair of the Zantac Litigation Group for AAJ – American Association for Justice.

Agenda

When to see them

Tuesday
April 13

11:45 am Zantac: Census, Criteria, and Case Update